Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, Leerink says the updated 12 month data highlights “impressive” 64% landmark OS, which the analyst calls “encouraging.” The median progression free survival deteriorated to 8.5 months, which the analyst notes is similar to the 8.5 months shown by Revolution Medicines’ (RVMD) daraxonrasib in second-line PDAC, but adds that Immuneering may have a safety advantage that “could facilitate a niche in frailer patients.” Leerink has a Outperform rating on Immuneering shares, which are down $3.37, or 40%, to $4.96 in afternoon trading.